Linda's deal sheet - detailed numbers are not the norm Take a look at Linda's deal sheet. If deals do have numbers, it is just upfront. A few large deals don't have upfront, half of the midsize deals have upfront and no small deals have numbers. This is normal course of business between big pharma and tiny biotechs. You want to play in the space... you play by big pharma rules. Don't think for a second retail investors can demand anything different.
In my opinion, this is a very encouraging deal. I have a lot of confidence, given Linda's negotiating experience, that the deal's value is fair and bodes well for SBM future.
Congrats to Sirona's team. It took longer that all of us would have liked, but in the end Well done!
GLTA